BRIEF-Lilly's Mirikizumab Helps Patients Achieve Clinical Remission And Improves Symptoms In Adults With Ulcerative Colitis In 12-Week Phase 3 Induction Study

Reuters · 03/16/2021 10:51
BRIEF-Lilly's Mirikizumab Helps Patients Achieve Clinical Remission And Improves Symptoms In Adults With Ulcerative Colitis In 12-Week Phase 3 Induction Study

- Eli Lilly and Co LLY.N:

  • LILLY'S MIRIKIZUMAB HELPS PATIENTS ACHIEVE CLINICAL REMISSION AND IMPROVES SYMPTOMS IN ADULTS WITH ULCERATIVE COLITIS IN 12-WEEK PHASE 3 INDUCTION STUDY

  • ELI LILLY AND CO - PATIENTS TREATED WITH MIRIKIZUMAB MET PRIMARY ENDPOINT OF CLINICAL REMISSION AND ALL KEY SECONDARY ENDPOINTS COMPARED TO PLACEBO

Source text for Eikon: ID:nPn4mlWbYa

Further company coverage: LLY.N


((Reuters.Briefs@thomsonreuters.com;))